DiaMedica Therapeutics Announces Publication of DM199s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed...